Edity Therapeutics
Using Human Immune Cells to Deliver Therapeutic Proteins
StartupEdity Therapeutics is a Rehovot-based startup in the Health Tech & Life Sciences sector, established in 2019. Using Human Immune Cells to Deliver Therapeutic Proteins. The company has raised a total of $13.63M across 3 funding rounds, currently at the A stage. Edity Therapeutics was founded by Eyal Kolka, Michal Golan Mashiach, Yoav Manaster. Key investors include Dr. Reddy's Laboratories, OurCrowd, Loop Ventures, among 7 total investors. The company has 11-50 employees. Core technologies: Biologicals, Genes.
With $13.63M in total funding, Edity Therapeutics is a A-stage company operating in Health Tech & Life Sciences. The company follows a B2B business model. Product stage: R&D. The company holds 1 patent.
- StageA
- ProductR&D
- ModelB2B
- Employees11-50
- HQRehovot
- Last Round$11.1M
- Dr. Reddy's Laboratories
- OurCrowd
- Loop Ventures
7 investors total
Eyal KolkaCo-founder & Chairman of Board
Michal Golan MashiachCo-founder & CEO
Yoav ManasterCo-founder
1 article covered by sources including www.webwire.com.
What does Edity Therapeutics do?
Edity is developing an exciting new platform that harnesses the immune system to deliver therapeutic proteins direct to the cytoplasm of target cells to reprogram cells and tissue back to health. The technology creates the opportunity to change the course of disease at the intracellular level via multiple mechanisms including protein replacement, target modulation, genetic correction and protein gain of function. Currently, the company is working across a number of indications, including oncology and genetic disease, while developing programs for regeneration and longevity.
How much funding has Edity Therapeutics raised?
Edity Therapeutics has raised $13.63M in total funding across 3 rounds. The company is currently at the A stage. Key investors include Dr. Reddy's Laboratories, OurCrowd, Loop Ventures.
Who founded Edity Therapeutics?
Edity Therapeutics was founded in 2019 by Eyal Kolka (Co-founder & Chairman of Board), Michal Golan Mashiach (Co-founder & CEO), Yoav Manaster (Co-founder).
What sector is Edity Therapeutics in?
Edity Therapeutics operates in Health Tech & Life Sciences, Pharma & Medical Biotechnology, Drugs Discovery & Development, with core technologies in Biologicals, Genes. Target customers: Healthcare & Life Sciences, Life Sciences, Biotechnology.
Where is Edity Therapeutics located?
Edity Therapeutics is based in Prof. Menakhem Plaut St, Rehovot, Israel.